Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
Scientists at the Department of Energy Manufacturing Demonstration Facility at ORNL have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023.
Researchers at the Department of Energy’s Oak Ridge National Laboratory are refining their design of a 3D-printed nuclear reactor core, scaling up the additive manufacturing process necessary to build it, and developing methods
OAK RIDGE, Tenn., Feb. 19, 2020 — The U.S. Department of Energy’s Oak Ridge National Laboratory and the Tennessee Valley Authority have signed a memorandum of understanding to evaluate a new generation of flexible, cost-effective advanced nuclear reactors.
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.